Who are zidovudine+lamivudine+lopinavir/ritonavir's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): TAF with a boosted protease inhibitor, Combivir+Kaletra, ZDV+3TC+LPV/r, AZT+3TC+IDV+RTV.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/zidovudine-lamivudine-lopinavir-ritonavir.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

zidovudine+lamivudine+lopinavir/ritonavir — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

zidovudine+lamivudine+lopinavir/ritonavir (zidovudine+lamivudine+lopinavir/ritonavir) competitive landscape: 4 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antiretroviral combination therapy (NRTI + PI). Area: Infectious Disease / Virology.

marketed Antiretroviral combination therapy (NRTI + PI) HIV reverse transcriptase and HIV protease Infectious Disease / Virology Small molecule Live · refreshed every 30 min

Target snapshot

zidovudine+lamivudine+lopinavir/ritonavir (zidovudine+lamivudine+lopinavir/ritonavir) — Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran. This combination inhibits HIV replication by blocking reverse transcriptase (zidovudine and lamivudine) and protease (lopinavir/ritonavir) enzymes required for viral reproduction.

Comparator set (4 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
zidovudine+lamivudine+lopinavir/ritonavir TARGET	zidovudine+lamivudine+lopinavir/ritonavir	Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran	marketed	Antiretroviral combination therapy (NRTI + PI)	HIV reverse transcriptase and HIV protease
TAF with a boosted protease inhibitor	TAF with a boosted protease inhibitor	University of Colorado, Denver	marketed	Antiretroviral combination (nucleotide reverse transcriptase inhibitor + protease inhibitor)	HIV reverse transcriptase and HIV protease
Combivir+Kaletra	Combivir+Kaletra	Hospital Clinic of Barcelona	marketed	Antiretroviral combination therapy (NRTI + protease inhibitor)	HIV reverse transcriptase and HIV protease
ZDV+3TC+LPV/r	ZDV+3TC+LPV/r	International Maternal Pediatric Adolescent AIDS Clinical Trials Group	marketed	Antiretroviral combination therapy (NRTI + PI)	HIV reverse transcriptase; HIV protease
AZT+3TC+IDV+RTV	AZT+3TC+IDV+RTV	Hospital Clinic of Barcelona	marketed	Antiretroviral combination therapy (NRTI + PI)	HIV reverse transcriptase; HIV protease

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antiretroviral combination therapy (NRTI + PI) class)

Hospital Clinic of Barcelona · 1 drug in this class
Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran · 1 drug in this class
International Maternal Pediatric Adolescent AIDS Clinical Trials Group · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). zidovudine+lamivudine+lopinavir/ritonavir — Competitive Intelligence Brief. https://druglandscape.com/ci/zidovudine-lamivudine-lopinavir-ritonavir. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab